• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » High-Dose Aspirin and Age Are the Only Convincing Depression Risk Factors in Late Life
Research Update

High-Dose Aspirin and Age Are the Only Convincing Depression Risk Factors in Late Life

October 1, 2024
Kathryn Kieran, MSN, PMHNP-BC
From The Carlat Geriatric Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Kathryn Kieran, MSN, PMHNP-BC. Ms. Kieran has no financial relationships with companies related to this material.

REVIEW OF: Wu Q et al, J Affect Disord 2022;307:37–45

STUDY TYPE: Meta-analysis of placebo-controlled trials 

It’s difficult to evaluate risk factors for something as complex as depression. This umbrella review combed through systematic reviews and meta-analyses to identify risk and protective factors for depression in adults 60 years and older and to evaluate the quality of the evidence. Ideally, if we could identify modifiable risk factors early on, we could intervene to reduce an individual’s depression risk. 

The authors included 22 meta-analyses and three systematic reviews to look at 82 associations (risk and protective factors) in a total of 1,199,927 participants. They evaluated 48 associations quantitatively, with more than 60% indicating nominal statistical significance. Two factors, “high-dose” (500 mg) daily aspirin and age greater than 80 years, had the strongest evidence as risk factors for depression. Four additional risk factors were highly suggestive: sleep disturbances, hearing problems, vision problems, and cardiac disease. In terms of protective factors, the authors found an association between a healthy diet (odds ratio [OR] 0.85), omega-3 fatty acid intake (OR 0.74), and physical activity (OR 0.81).

There were a number of limitations with this study. Unfortunately, low-quality and even critically low-quality studies were included. Also, the authors did not evaluate studies focusing on subtypes of depression (eg, poststroke, dysthymia). 

Carlat Take

The evidence for risk factors for depression in older adults is surprisingly poor when subject to strict analysis. Keep a close eye on patients with a high medical burden and visual or hearing impairments. Encourage patients to eat well and keep moving. Unlike low-dose aspirin (75–150 mg), which is primarily used for the prevention of cardiovascular and thromboembolic events, high-dose aspirin is primarily used for pain relief and may be a marker for medical morbidity in these studies. Reassuringly, low-dose aspirin does not seem to increase ­depression.

Geriatric Psychiatry
KEYWORDS depression late life depression Older adults
    Kathryn Kieran, MSN, PMHNP-BC

    Large Longitudinal Study Links Mild Depression and Dementia

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objective, Health Equity, October/November/December 2024
    News of Note: Donanemab Gains FDA Approval for Early Alzheimer’s Treatment
    How to Talk to Patients About Ageism and Racism
    Disparities in Dementia Diagnosis
    Considerations in Prescribing Lithium in Older Adults
    Reevaluating Diagnosis Criteria for Minoritized Populations
    Moderate Alcohol Use and ­Cognitive Decline
    High-Dose Aspirin and Age Are the Only Convincing Depression Risk Factors in Late Life
    CME Post-Test, Health Equity, CGPR, October/November/December 2024
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.